The use of one or more cannabinoids with one or more anti-psychotic medicaments in the manufacture of a medicament for use in the treatment of psychosis and related disorders is disclosed. The one or more cannabinoids are preferably taken from the group containing cannabidiol (CBD), cannabidiolic acid (CBDA), tetrahydrocannbidivarin (THCV), tetrahydrocannbidivarinin acid (THCVA), cannabichromene (CBC), cannabichromenic acid (CBCA), cannabigerol (CBG), and cannabigerolic acid (CBGA). The anti-psychotic medication is preferably an atypical anti-psychotic medication such as aripiprazole, risperidone, paliperidone, ziprasidone, olanzapine, quetiapine, clozapine, or sulpiride, among others. The cannabinoids are shown to have metabolic and cardiovascular effects which can be useful in combined treatments with anti-psychotic medicaments. Methods of treatment using the compositions are also disclosed.
